Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

While its customers are losing weight, Novo Nordisk, the creator of the mega-hit drug Ozempic, is shedding loads of market ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Novo Nordisk A/S (NYSE: NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), ...

By Twesha Dikshit and Ragini Mathur (Reuters) -European shares logged their biggest daily rise in over two weeks on Thursday, ...

AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...